Apaziquone - Assertio Therapeutics
Alternative Names: EO 9; EOquin; Neoquin; NOR-701; NSC 382459; QapzolaLatest Information Update: 12 Jan 2024
At a glance
- Originator Spectrum Pharmaceuticals
- Developer Handok Inc; Nippon Kayaku; Spectrum Pharmaceuticals
- Class Aziridines; Cytostatic antibiotics; Indolequinones; Small molecules
- Mechanism of Action Alkylating agents; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bladder cancer; Leucoplakia
Most Recent Events
- 06 Oct 2021 Discontinued - Phase-I/II for Leucoplakia in India (Topical)
- 06 Oct 2021 Discontinued - Phase-II for Bladder cancer (Adjuvant therapy) in Japan (Intravesicular)
- 06 Oct 2021 Discontinued - Phase-II for Bladder cancer in Netherlands, United Kingdom (Intravesicular)